alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,576–1,600 of 2,931 studies published 2025 · free to read (page 64 of 118) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Cerebrospinal fluid YKL‐40 relates to white matter hyperintensity progression in females but not males over a 6‐year period

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-04-01

= 0.71) longitudinally. YKL-40 associations with FW and FW-corrected fractional anisotropy were null. 4 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Associations between stroke and vascular dementia combing Mendelian randomization with network pharmacology

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Medicine 2025-02-21

The results of the inverse variance weighted analysis demonstrate a significant positive causal relationship between stroke and VaD (OR = 2.06, 95% confidence interval [CI] = 1.17-3.61, P = .01). 5 key findings →

Participants: 222 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID)

✓ Peer-reviewed alzhub usefulness score 43 out of 100. GeroScience 2025-04-11

Vascular contributions to cognitive impairment and dementia (VCID) represent a major public health challenge in the aging population, with age-related cerebromicrovascular dysfunction playing a critical role in its development. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Synergistic impacts of physical activity and sleep on risk of dementia and all-cause mortality in Chinese older stroke survivors

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Stroke and Cerebrovascular Diseases 2025-12-11

Older stroke survivors engaging in regular PA had a 38 % reduced risk of dementia [Odds Ratio (OR) =0.62, 95 % Confidence Interval (CI): 0.56-0.69, P < 0.001] and a 44 % lower risk of mortality [Hazard Ratio (HR) =0.56, 95 % CI: 0.52-0.59, P < 0.001]. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Higher neighborhood deprivation is associated with accelerated disease progression in behavioral-variant frontotemporal degeneration

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia. Behavior & socioeconomics of aging 2025-06-04

Neighborhood deprivation is associated with shorter survival, cognitive impairment and neurodegeneration in aging and Alzheimer's disease. 3 key findings →

Design: longitudinal study Participants: 161 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mapping the research landscape of Mild Cognitive Impairment in Parkinson's disease: a bibliometric and visualization analysis

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in aging neuroscience 2025-09-10

Mild cognitive impairment in Parkinson's disease research has progressed from basic mechanism exploration to a multidisciplinary, integrated clinical-basic stage, following an evolutionary path of "pathological mechanism - clinical phenotype - biomarker - intervention strategy." 2 key findings →

Design: systematic review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Enhancing protein O-GlcNAcylation in down syndrome mice mitigates memory dysfunctions through the rescue of mitochondrial bioenergetics, stress responses and pathological markers

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Redox biology 2025-07-16

Disturbances of the single sugar modification of proteins, O-GlcNAc, have been identified as a potential connection between disrupted brain metabolism and intellectual decay. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Trends in the use of advance care planning and cognitive assessment and care planning service visits: moving toward a palliative‐informed approach for ambulatory care of community‐dwelling persons with dementia and their caregivers

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-04-01

For 2018 and 2019, 3.5% and 5.4% received ACP visits, and 0.4% and 0.5% received CAACPS visits, similar to use reported elsewhere. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer’s Disease Dementia Prevalence in the United States: A County-Level Spatial Machine Learning Analysis

✓ Peer-reviewed alzhub usefulness score 42 out of 100. American Journal of Alzheimer s Disease & Other Dementias® 2025-04-21

A growing body of literature has examined the impact of neighborhood characteristics on Alzheimer’s disease (AD) dementia, yet the spatial variability and relative importance of the most influential factors remain underexplored. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Examining equity in service use across socioeconomic status in people with dementia

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia Behavior & Socioeconomics of Aging 2025-02-19

Stark differences across SES in service use by people with dementia may indicate different health needs and/or allude to pervasive health inequities. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Characterization of Hispanic, African American, and non‐Hispanic White individuals living in disadvantage neighborhoods: the HABS‐HD Study

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-12-01

In the whole sample, significant differences between ethnicities were found in demographic, SE, psychological, and health variables. 5 key findings →

Participants: 2,833 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Inflammatory Alterations and Multidomain Cognition in Alzheimer Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer Disease & Associated Disorders 2025-10-01

Greater TSPO is associated with lower performance in episodic memory, attention/processing speed, executive function, language, and visuospatial ability in amyloid-positive individuals, but restricted to episodic memory in amyloid-negative individuals. 2 key findings →

Design: cross-sectional Participants: 21 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer disease blood biomarkers and cognition in midlife

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-12-01

Older age, White race, APOE ε4 carrier, and diabetes were associated with biomarker levels indicative of higher AD risk (lower Aβ42/40; higher p-tau217, p-tau217/Aβ42, NfL, and GFAP). 5 key findings →

Participants: 1,356 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Neurological Sciences 2025-10-17

This joint Position Paper, developed by the Italian Expert Panel on Alzheimer convened by the Italian Society of Neurology with participation from multiple scientific societies, outlines strategic guidelines for reorganizing the patient journey in the era of anti-amyloid monoclonal antibodies for Alzheimer's disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A novel C. elegans model for MAPT/Tau spreading reveals genes critical for endolysosomal integrity and seeded MAPT/Tau aggregation

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Autophagy 2025-08-25

The spreading of MAPT/Tau pathology is closely associated with the progression of neurodegeneration and cognitive decline in Alzheimer disease and other tauopathies. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

APOE‐Genotype Modifies the Association of Meat Consumption with Cognitive Decline: Longitudinal Analyses of The Swedish National Study on Aging and Care, SNAC‐K

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-12-01

Higher total meat consumption (red meat: 51%, poultry: 20%, processed meat: 29%), was associated with a better cognitive trajectory only in the APOE34/44 stratum (β per 1 z-unit increase: 0.011; CI: 0.004 to 0.018 versus -0.003; CI: -0.008 to 0.003; P for interaction = 0.002). 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies

✓ Peer-reviewed alzhub usefulness score 42 out of 100. American Journal of Neuroradiology 2025-07-10

Alzheimer disease (AD) is the leading cause of dementia, with an estimated 6.9 million Americans aged 65 and older living with Alzheimer dementia today, with this number projected to grow to 13.8 million by 2060. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence–Assisted Detection of Amyloid-Related Imaging Abnormalities: Promise and Pitfalls

✓ Peer-reviewed alzhub usefulness score 42 out of 100. American Journal of Neuroradiology 2025-07-30

The advent of anti-amyloid therapies (AATs) for Alzheimer disease (AD) has elevated the importance of MRI surveillance for amyloid-related imaging abnormalities (ARIA) such as microhemorrhages and siderosis (ARIA-H) and edema (ARIA-E). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Leveraging digital twins for sample size reduction, powering secondary endpoints or subgroups in a simulated TRAILBLAZER‐ALZ 2 trial

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-12-01

Due to the reduced variability in endpoints when using digital twins as covariates in statistical analyses, the TRAILBLAZER-ALZ 2 trial could have enrolled up to 24% fewer control arm participants to draw the same conclusions about treatment efficacy as previously reported for the study's primary outcome, the integrated Alzheimer Disease Rating Scale (iADRS) at 18 months. 4 key findings →

Design: longitudinal study Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events